For the Inventor, By the Inventor

Enter assignee name

Leiden, Netherlands

Crucell Holland B.v.

Calculating rank

USPTO Granted Patents = 146

% Expired Patents = 50.7

CIPO Patents = 2

EPO Patents = 55

Trademarks = 2

Forward Citations = 2,177

Loading Chart...

Loading Chart...

111 inventors (with patents filed for the assignee):

Ronald Vogels (37 out of 50 patents)

Abraham Bout (33 out of 55 patents)

Cornelis Adriaan De Kruif (24 out of 54 patents)

4. Maria Grazia Pau (18 out of 30 patents)

5. Mark Throsby (17 out of 50 patents)

6. Menzo Jans Emco Havenga (16 out of 16 patents)

7. Lennart Holterman (11 out of 11 patents)

8. Govert Johan Schouten (10 out of 17 patents)

9. Alphonsus G C M UytdeHaag (10 out of 10 patents)

10. Menzo Havenga (9 out of 9 patents)

11. Alexander Berthold Hendrik Bakker (8 out of 17 patents)

12. Ton Logtenberg (7 out of 59 patents)

13. Jorn Kaspers (7 out of 7 patents)

14. Antonius J H Stegmann (7 out of 8 patents)

15. Domenico Valerio (7 out of 21 patents)

Core Competencies:

Influenza Virus

Adenoviral Vectors

RSV Antibodies

Recombinant Vaccines

Virus Neutralization

Binding Molecules

Vaccine Production

Therapeutic Vaccination

Gene Delivery

Immunoglobulin Libraries

Viral Purification

Cell Lines

146 patents: Sort by Forward Citations

1. 9611317 - Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof (2017-04-04),

2. 9428768 - Method for the production and purification of adenoviral vectors (2016-08-30),

3. 9403900 - Anti-human respiratory syncytial virus (RSV) antibodies and methods of use (2016-08-02),

4. 9365638 - Antibodies against human respiratory syncytial virus (RSV) and methods of use (2016-06-14),

5. 9228205 - Complementing cell lines (2016-01-05),

6. 9200064 - Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof (2015-12-01),

7. 9168292 - Heterologous prime boost vaccination regimen against malaria (2015-10-27),

8. 9139642 - Anti-human respiratory syncytial virus (RSV) antibodies and methods of use (2015-09-22),

9. 9125870 - Vaccine against RSV (2015-09-08),

10. 9119813 - Vaccine against RSV (2015-09-01),

11. 9109017 - Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof (2015-08-18),

12. 9022240 - Production of poliovirus at high titers for vaccine production (2015-05-05),

13. 9011848 - Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof (2015-04-21),

14. 9005624 - Binding molecules capable of neutralizing rabies virus and uses thereof (2015-04-14),

15. 9005621 - Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof (2015-04-14),

Company Overview

Crucell Holland B.V., based in Leiden, Netherlands, specializes in the development and production of innovative vaccines. The company focuses on advanced technologies in vaccine research, particularly in areas such as influenza virus, adenoviral vectors, and respiratory syncytial virus (RSV) antibodies. With expertise in recombinant vaccines and virus neutralization, Crucell is dedicated to enhancing therapeutic vaccination strategies and improving vaccine production processes, contributing significantly to global health initiatives.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

146 Patents

#1 in Leiden

#64 in Netherlands

#5,580 in the World

Leiden, Netherlands

Crucell Holland B.v.

Forward Citations = 2,177

111 inventors:

Ronald Vogels (37 out of 50 patents)

Abraham Bout (33 out of 55 patents)

Cornelis Adriaan De Kruif (24 out of 54 patents)

4. Maria Grazia Pau (18 out of 30 patents)

5. Mark Throsby (17 out of 50 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Crucell Holland B.v.. Retrieved from https://idiyas.com/company/crucell-holland-b-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…